SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
- Sort by:
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
102
|
RECENT ADVANCES IN THE DIAGNOSIS, TREATMENT, AND PREVENTION OF TUBERCULOSIS (ABSTRACT
111)
Gavin Churchyard
Aurum Institute, Johannesburg, Gauteng, South Africa
ENGINEERING VACCINE IMMUNITY (ABSTRACT
112)
Shane Crotty
La Jolla Institute for Immunology, La Jolla, CA, USA
DOLUTEGRAVIR-CONTAINING ART DOES NOT REDUCE ETONOGESTREL IMPLANT CONCENTRATIONS (ABSTRACT
129)
Rena Patel
University of Washington, Seattle, WA, USA
SAFETY AND EFFICACY OF DTG VS EFV AND TDF VS TAF IN PREGNANCY: IMPAACT 2010 TRIAL (ABSTRACT
130)
Lameck Chinula
University of North Carolina Project-Malawi, Lilongwe, Malawi, Malawi
DIFFERENTIATED CARE FOR POSTPARTUM ART IN SOUTH AFRICAN WOMEN LIVING WITH HIV: AN RCT (ABSTRACT
131)
Jasantha Odayar
University of Cape Town, Cape Town, Western Cape, South Africa
POC EID VS CENTRAL LAB TESTING: RESULTS FROM A STEP-WEDGE RCT IN KENYA AND ZIMBABWE (ABSTRACT
132)
Emma Sacks
Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA
A RANDOMIZED TRIAL OF POINT-OF-CARE EARLY INFANT HIV DIAGNOSIS IN ZAMBIA (ABSTRACT
133)
Carla J. Chibwesha
University of North Carolina Chapel Hill, Chapel Hill, NC, USA
POPULATION-LEVEL HIV-FREE INFANT SURVIVAL IN THE SEARCH TRIAL (ABSTRACT
134)
Theodore Ruel
University of California, San Francisco, San Francisco, CA, USA
PREDICTORS OF THE PERSISTING VIRAL RESERVOIR IN VERY EARLY TREATED INFANTS (ABSTRACT
135)
Louise Kuhn
Columbia University, New York, NY, USA
LONG-TERM TREATMENT OUTCOMES: EARLY VERSUS DEFERRED ART IN CHILDREN LIVING WITH HIV (ABSTRACT
136)
Thanyawee Puthanakit
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
INFERIORITY OF SHORT DURATION SOFOSBUVIR-VELPATASVIR FOR RECENT HCV (REACT STUDY) (ABSTRACT
121)
Gail Matthews
Kirby Institute, Sydney, Australia
INDIVIDUAL AND POPULATION-LEVEL IMPACT OF HCV TREATMENT AMONG PEOPLE WHO INJECT DRUGS (ABSTRACT
122)
Javier Cepeda
University of California San Diego, LA JOLLA, CA, USA
LARGE HIV OUTBREAK AMONG PEOPLE WHO INJECT DRUGS, WEST VIRGINIA, 2018–2019 (ABSTRACT
123)
Robert Paul McClung
Centers for Disease Control and Prevention, Atlanta, GA, USA
HCV TRANSMISSION AMONG MSM: EXTERNAL INTRODUCTIONS COULD COMPLICATE MICRO-ELIMINATION (ABSTRACT
124)
Jelle Koopsen
Amsterdam University Medical Center, Amsterdam, Netherlands
NEWBORN TESTING REVEALS HIGH HCV SEROPREVALENCE IN PREGNANT WOMEN FROM NEW YORK STATE (ABSTRACT
125)
Linda M Styer
New York State Department of Health, Albany, NY, USA
HEPATOCELLULAR CARCINOMA RISK AMONG PERSONS WITH HIV IN NORTH AMERICA, 1996-2015 (ABSTRACT
126)
Jing Sun
Johns Hopkins University, Baltimore, MD, USA
HIV/HCV VS HCV: PLASMA AND LIVER VIRAL DYNAMICS AND IP-10 LEVELS (ABSTRACT
127)
Ashwin Balagopal
Johns Hopkins University, Baltimore, MD, USA
CLINICAL PREDICTORS OF LIVER FIBROSIS PRESENCE & PROGRESSION IN HIV-ASSOCIATED NAFLD (ABSTRACT
128)
Lindsay T Fourman
Massachusetts General Hospital, Boston, MA, USA
IL-6 BLOCKADE DECREASES INFLAMMATION AND INCREASES CD127 EXPRESSION IN HIV INFECTION (ABSTRACT
113)
Benigno Rodriguez
Case Western Reserve University, Cleveland, OH, USA
NEUTRALIZING ANTIBODIES AND TRMS PROVIDE ENHANCED AND DURABLE RESISTANCE AGAINST HIV (ABSTRACT
114)
Prabhu S Arunachalam
Stanford University, Palo Alto, CA, USA
HUMAN NK CELLS DEVELOP ANTIGEN-SPECIFIC IMMUNOLOGICAL MEMORY OF HIV (ABSTRACT
115)
Stephanie Jost
Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA, USA
EFFICACIOUS RHCMV/SIV VECTORS ELICIT BROADLY CROSS-REACTIVE SIV-SPECIFIC CD8+ T CELLS (ABSTRACT
116)
Benjamin N Bimber
Oregon Health & Science University, Beaverton, OR, USA
PD-1 BLOCKADE AT TIME OF ART WITHDRAWAL FACILITATES EARLY POST-PEAK VIRAL CONTROL (ABSTRACT
117)
Afam Okoye
Oregon Health and Science University, Beaverton, OR, USA
TRACKING AND PREDICTING REBOUND IN SHIV-INFECTED INFANT MACAQUES AFTER LONG-TERM ART (ABSTRACT
118)
Veronica Obregon-Perko
Emory University, Atlanta, GA, USA
PERIPHERAL BLOOD SIV/HIV ORIGINATES FROM INFECTED CELLS IN TISSUES (ABSTRACT
119)
Leticia Kuri Cervantes
University of Pennsylvania, Philadelphia, PA, USA
CD4+ T-CELL DEPLETION IN AFRICAN GREEN MONKEYS DOES NOT ALTER DISEASE PROGRESSION (ABSTRACT
120)
Christian Apetrei
University of Pittsburgh, Pittsburgh, PA, USA
NO HIV INCIDENCE INCREASE IN FIRST-TIME BLOOD DONORS WITH 12-MONTH DEFERRAL FOR MSM (ABSTRACT
145)
Eduard Grebe
Vitalant Research Institute, San Francisco, CA, USA
EXPLAINING RACIAL DISPARITIES IN VIRAL SUPPRESSION AMONG MSM LIVING WITH HIV (ABSTRACT
146)
Justin Ryan Knox
Columbia University, New York, NY, USA
EXPLOSIVE HIV AND HCV EPIDEMICS DRIVEN BY NETWORK VIREMIA AMONG PWID (ABSTRACT
147)
Sunil S. Solomon
Johns Hopkins University School of Medicine, BALTIMORE, MD, USA
THE AGING OF HIV-1 INCIDENCE IN HYPERENDEMIC RURAL SOUTH AFRICA (ABSTRACT
148)
Adam N. Akullian
Institute for Disease Modeling, Bellevue, WA, USA
HIGH HIV INCIDENCE IN YOUNG WOMEN IN THE BOTSWANA COMBINATION PREVENTION PROJECT (ABSTRACT
149)
Faith Ussery
Centers for Disease Control, Atlanta, GA, USA
RAPIDLY DECLINING HIV INCIDENCE AMONG MEN AND WOMEN IN RAKAI, UGANDA (ABSTRACT
150)
Mary K Grabowski
Johns Hopkins School of Medicine, Baltimore, MD, USA
INCREASED OVERALL LIFE EXPECTANCY BUT NOT COMORBIDITY-FREE YEARS FOR PEOPLE WITH HIV (ABSTRACT
151)
Julia L. Marcus
Harvard Medical School, Boston, MA, USA
LOW-LEVEL VIREMIA DURING ART AND THE RISK OF DEATH, AIDS, AND SERIOUS NON-AIDS EVENTS (ABSTRACT
152)
Olof Elvstam
Lund University, Malmö, Sweden
ANTIMICROBIAL PROPHYLAXIS AMONG AFRICAN ADULTS ON ART: RESULTS OF A RANDOMIZED TRIAL (ABSTRACT
137)
Randy George Mungwira
World Health Organization, Lilongwe, Malawi
ISONIAZID TO PREVENT MTB INFECTION IN HIV-EXPOSED UNINFECTED INFANTS (ABSTRACT
138)
Sylvia LaCourse
University of Washington, Seattle, WA, USA
PREDICTORS OF TUBERCULOSIS INFECTION IN MDR-TB HOUSEHOLD CONTACTS ≥15 YEARS OLD (ABSTRACT
139)
Soyeon Kim
Frontier Science Foundation, Brookline, MA, USA
DIAGNOSTIC AND THERAPEUTIC CHALLENGES ARISE WITH EARLY HIV INFECTION ON PREP (ABSTRACT
140)
Michael J Peluso
University of California San Francisco, San Francisco, CA, USA
A RANDOMIZED TRIAL OF INCENTIVES AND DEPOSIT CONTRACTS TO PROMOTE HIV RETESTING (ABSTRACT
141)
Gabriel Chamie
University of California, San Francisco, San Francisco, CA, USA
COMMUNITY-BASED HIV TESTING IN URBAN KENYA: A STRATEGY TO REACH MEN AND YOUTH (ABSTRACT
142)
Hong-Ha M. Truong
University of California, San Francisco, San Francisco, CA, USA
EFFECTIVENESS OF 3HP ANNUALLY VS ONCE FOR HIV-POSITIVE PEOPLE: THE WHIP3TB TRIAL (ABSTRACT
143)
Gavin Churchyard
Aurum Institute, Johannesburg, Gauteng, South Africa
RIFAPENTINE PHARMACOKINETICS AND SAFETY IN PREGNANT WOMEN WITH AND WITHOUT HIV ON 3HP (ABSTRACT
144)
Jyoti S. Mathad
Weill Cornell Medicine, New York, USA, NY, USA
SESSION INTRODUCTION
Linos Vandekerckhove
Ghent University, Ghent, Belgium
PARALLEL HIV RNA, INTEGRATION SITE, AND PROVIRAL SEQUENCING IN SINGLE RESERVOIR CELLS (ABSTRACT
360)
Kevin Einkauf
Brigham and Women's Hospital, Cambridge, MA, USA
SINGLE-CELL ATLAS AND CLONAL EXPANSION DYNAMICS OF CD4+ T CELLS DURING HIV INFECTION (ABSTRACT
361)
Jack A Collora
Yale University, New Haven, CT, USA
|
<< first | < prev
page:
of 3
|
records per page:
next >
| last >>
|
| pages: 1 2 3
|
presentations:
1 to
50 of
102
|
